Nektar Therapeutics announced the publication of preclinical data in Blood Advances, the open-access journal of the American Society of Hematology, highlighting the effects of NKTR-255, a novel polymer-conjugated human IL-15, on the efficacy of human CD19 CAR-T cells in a xenogeneic lymphoma model and on CD8+ T effector cell (Tcell) and natural killer (NK) cell proliferation in non-human primates. The data from this publication demonstrate that NKTR-255 not only enhanced in vivo proliferation and accumulation of T and NK cells in non-human primates, but also demonstrated enhanced in vivo antitumor efficacy of human CD19 CAR-T in lymphoma-bearing immunodeficient mice. Key findings are summarized below: Serum IL-15 concentration is independently associated with longer CD19 CAR-T persistence in humans, NKTR-255 promotes CD8+ effector and memory T and NK cell accumulation in non-human primates, NKTR-255 enhances proliferation and survival of human CD19 CAR-T at low target cell abundance and NKTR-255 enhances accumulation and efficacy of human CD19 CAR-T in lymphoma bearing immunodeficient mice.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.65 USD | +5.10% | +13.01% | +192.04% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+192.04% | 288M | |
+31.52% | 662B | |
+21.96% | 546B | |
-5.21% | 359B | |
+17.02% | 323B | |
+5.01% | 289B | |
+13.68% | 234B | |
+3.81% | 198B | |
-10.63% | 194B | |
+3.98% | 167B |
- Stock Market
- Equities
- NKTR Stock
- News Nektar Therapeutics
- Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, A Novel Polymer-Conjugated Human IL-15, Improves Efficacy of CD19-Targeted CAR-T Cell Immunotherapy